The death rate of pulmonary fibrosis patients who were put on a hospital ventilator was seven times higher than those treated without a ventilator, according to a review of thousands of medical records. The study of 22,350 admissions also showed that the cost of treating patients who were put on…
Prometic’s PBI-4050 leveled off idiopathic pulmonary fibrosis patients’ decline in lung function, indicating it is a promising treatment for the disease, according to a Phase 2 clinical trial. The leveling occurred when PBI-4050 was used by itself and when it was used in one of two combination therapies. IPF…
NuMedii, a company that applies computer-based artificial intelligence (AI) to medical analysis, has teamed up with Three Lakes Partners, a Chicago-based investment and philanthropic organization, to develop drugs to treat idiopathic pulmonary fibrosis (IPF). Pulmonary fibrosis is a lung disorder that involves scarring of the lungs, leading to serious breathing…
An 84-year-old man diagnosed with an acute exacerbation of idiopathic pulmonary fibrosis (IPF) was successfully treated with Ofev (nintedanib) without antibiotics or steroids, according to a case study detailed in the journal Respirology Case Reports. Ofev, an approved treatment in the United States and EU, is a tyrosine kinase inhibitor that works to…
Get regular updates to your inbox.
